Evolution of the Average Target: NeoGenomics, Inc.

Evolution of the Average Target - NeoGenomics, Inc.

Evolution of the Target Price: NeoGenomics, Inc.

Evolution of the Target Price - NeoGenomics, Inc.

Changes in Analyst Recommendations: NeoGenomics, Inc.

ad17ce716cf67256b888.03a3PABzaqBm-Hi_v-bHAUqxHKWHKunCaykTztSHYR8._jiEclgdK9IPsRbb-d_2eRrSW-fBHKT6KUVlgLy-LkelJtxVdBgcxiSJQA~21c85283b9ea21f5815951f894f43e23
10-06 NeoGenomics on 'More Solid Footing' With Strong Revenue Growth, Needham Says MT
10-06 Needham & Co Adjusts NeoGenomics Price Target to $22 From $19, Maintains Buy Rating MT
10-06 BTIG Upgrades NeoGenomics to Buy From Neutral, Price Target is $28 MT
07-29 Needham Raises Price Target on NeoGenomics to $19 From $15, Keeps Buy Rating MT
04-29 Leerink Upgrades NeoGenomics to Outperform From Market Perform, Adjusts Price Target to $25 From $12 MT
25-07-30 BTIG Research Downgrades NeoGenomics to Neutral From Buy MT
25-07-18 BofA Securities Adjusts NeoGenomics Price Target to $8 From $10, Maintains Neutral Rating MT
25-05-15 Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating MT
25-04-30 Leerink Partners Downgrades NeoGenomics to Market Perform From Outperform, Lowers Price Target to $9 From $25 MT
25-04-29 Top Midday Decliners MT
25-04-29 Needham Cuts NeoGenomics' Price Target to $8.50 From $18, Maintains Buy Rating MT
25-04-14 BofA Securities Adjusts Price Target on NeoGenomics to $12 From $16, Maintains Neutral Rating MT
25-01-13 Benchmark Downgrades NeoGenomics to Hold From Buy MT
24-12-10 Jefferies Initiates NeoGenomics at Buy With $22 Price Target MT
24-04-30 Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating MT
24-02-26 Piper Sandler Adjusts Price Target on NeoGenomics to $20 From $18, Maintains Overweight Rating MT
24-02-22 Goldman Sachs Raises Price Target on NeoGenomics to $19 From $17, Maintains Buy Rating MT
24-02-21 Needham Raises NeoGenomics' Price Target to $24 From $21, Keeps Buy Rating MT
23-12-29 TD Cowen Cuts Price Target on NeoGenomics to $19 From $22, Maintains Outperform Rating MT
23-12-29 BTIG Cuts Price Target on NeoGenomics to $21 From $25, Keeps Buy Rating MT
23-10-24 Morgan Stanley Cuts Price Target on NeoGenomics to $16 From $18, Maintains Equal-Weight Rating MT
23-10-23 Goldman Sachs Cuts Price Target on NeoGenomics to $17 From $19, Maintains Buy Rating MT
23-10-20 BofA Securities Adjusts Price Target on NeoGenomics to $15 From $17, Maintains Neutral Rating MT
23-08-21 Stephens Upgrades NeoGenomics to Overweight From Equal-Weight, Price Target at $18 MT
23-08-09 TD Cowen Adjusts Price Target on NeoGenomics to $23 From $22, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+53.44%
+27.38%
-3.55%
+42.49%
+8.27%
+5.93%
+0.36%
+9.52%
+25.14%
+29.58%
Average +19.86%
Weighted average by Cap. +15.14%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.25USD
Average target price
23.40USD
Spread / Average Target
+53.44%
High Price Target
35.00USD
Spread / Highest target
+129.51%
Low Price Target
19.00USD
Spread / Lowest Target
+24.59%

Analyst Consensus Detail

Analyst consensus - NeoGenomics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - NeoGenomics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - NeoGenomics, Inc.
  1. Stock Market
  2. Stocks
  3. NEO Stock
  4. Consensus NeoGenomics, Inc.